Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating

CoffeeNFTs · 2026-03-27T17:31:25+00:00

Tarsus Pharmaceuticals received an upgrade in its Relative Strength Rating from 76 to 82, indicating improved performance. The stock is working on a consolidation pattern, with current recommendations for cautious market exposure amid volatility.

CoffeeNFTs

2026-03-27 17:31:25

Abstract generation in progress

On Thursday, Tarsus Pharmaceuticals (TARS) stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82.

				    ↑
					X

This video file cannot be played.(Error Code: 102630)

								Reading Between The Lines: How To Watch For Market Turns Through News Coverage
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						Reading Between The Lines: How To Watch For Market Turns Through News Coverage

Looking For The Best Stocks To Buy And Watch? Start Here

IBD’s proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price behavior over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history shows that the best-performing stocks often have an 80 or better RS Rating as they launch their biggest price moves.

Is Tarsus Pharmaceuticals Stock A Buy?

Tarsus Pharmaceuticals stock is working on a consolidation with an 85.25 entry. Given current stock market uncertainties and volatility, IBD recommends a cautious 0-20% market exposure. Be judicious with stock purchases.

Financial Performance And Industry Peers

The biotech company posted 0% EPS growth in its most recent report. Revenue rose 128%.

Tarsus Pharmaceuticals stock earns the No. 101 rank among its peers in the Medical-Biomed/Biotech industry group. Eton Pharmaceuticals (ETON), Kiniksa Pharmaceuticals (KNSA) and Amicus Therapeutics (FOLD) are among the top 5 highly rated stocks within the group. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”

This article was created automatically with Stats Perform’s Wordsmith software using data and article templates supplied by Investor’s Business Daily. An IBD journalist may have edited the article.

YOU MAY ALSO LIKE:

How To Know It’s Time To Sell Your Favorite Stock

How To Spot Stock Market Tops

Vertical Violations: Why You Should Recognize This Bear Market Indicator

When To Sell Growth Stocks: This Could Be Your No. 1 Rule

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes